Month: June 2016

Budapest Group recommendations at UNGASS 2016

At the beginning of 2016 the Budapest Group released Recommendations on EU Engagement at 2016 UN General Assembly Special Session (UNGASS) on Drugs

“The priority message of the Budapest Group is that civil society organizations must have a central role in the UNGASS deliberations, and that marginalized groups disproportionately impacted by drug policies, including women, youth, ethnic minorities and drug crop cultivators must be engaged in deliberations on, and the design, evaluation and monitoring of drug policies,” <br>explained SPP Associate Dean Julia Buxton.

The Budapest Group is a network of European NGOs working in the field of drug policy reform, including Harm Reduction International, the Global Drug Policy Program of the Open Society Foundations (OSF), the International Federation of Red Cross and Red Crescent Societies (IFRC), Transform Drug Policy Foundation, the International Drug Policy Consortium, the Hungarian Civil Liberties Union, and the Transnational Institute.

The text released from the Budapest Group is entitled: A call for EU leadership on drug policy: Principles and recommendations from EU civil society[1]for EU engagement at the 2016 UNGASS on drugs.

In the document is stated: “Member  states

should  advocate  for drug  policy evaluation  and metrics  that  relate directly to  the  key  pillars  of  the UN: human development, peace and security, and human rights, and recommend strategies,  metrics  and  approaches  that  are  informed  by  the  five  thematic  areas of the UNGASS.”

Commission on Narcotic Drugs decision on international control of acetylfentanyl and MT-45 enters into force

UNODC Early Warning System announced, on 17th May 2016, that the Commission on Narcotic Drugs – in its 59th Session from 16 to 22 March 2016 – decided that acetylfentanyl (Schedule I and IV) and MT-45 (Schedule I) will be added to the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol.

For more information check the links below:

https://www.unodc.org/LSS/Announcement/Details/3ec66e50-249f-438e-8a79-470d5e269b8d

http://www.un.org/ga/search/view_doc.asp?symbol=E/2016/28

https://www.unodc.org/unodc/en/commissions/CND/Mandate_Functions/Mandate-and-Functions_Scheduling.html

June 26th – International Day against Drug Abuse and illicit trafficking

The theme of this important day has been entitled: “Listen First”. It is a new acampaign and an initiative to increase support for prevention of drug use. It is an effective investment in the well-being of children and youth, and therefore families and communities. The basic message is simple: listening to children and youth is the first step to help them grow healthy and safe.

To know more on the campaign: https://www.unodc.org/listenfirst/

“On this International Day Against Drug Abuse and Illicit Trafficking, I call on countries and communities to continue to improve the lives of everyone blighted by drug abuse by integrating security and public safety with a heightened focus on health, human rights, and sustainable development.”
UN Secretary-General, Ban Ki-moon

2016 EU Drug Markets Report: In-depth Analysis

The 2016 EU Drug Markets Report provides an in-depth analysis and a unique insight into the illicit drug markets in the EU.

What can you find in the report?

  • An assessment of the impact of the drug market on society;
  • An exploration of the market for cannabis, heroin, cocaine, amphetamines, MDMA and new psychoactive substances;
  • The analysis of these hidden markets and the actors involved.

In the report the analytical power of the EMCDDA is combined with Europol’s operational intelligence. Drug markets are more and more dynamic, interlinked and connected to many of other critical policy issues in Europe. The report helps to address information needs and prove a state-of-the-art review.

EMCDDA Drug report 2016

EU drugs agency (EMCDDA) released the European Drug Report for 2016. The report investigates recent trends and development in drugs’ market and consume.

The highlighted topics are:

  • health risks of high-potency products;
  • emergence of new substances;
  • changing patterns of drug use;
  • overdose deaths in some countries
  • threats posed by internet drug markets.

It expresses the need for Europe to embrace a broader and more complicated set of policy issues